Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
Information source: Far Eastern Memorial Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Seretide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Far Eastern Memorial Hospital
Summary
In real life, the investigators will be using different strategies including SMART therapy
or other ICS/LABA (medium and high dose) therapy and measure the efficacy for asthma
control.
Clinical Details
Official title: Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: the percentage of asthma total and well control
Secondary outcome: percentage of asthma acute exacerbation
Detailed description:
1. All not-well controlled asthma patients would include the study.
2. We will compare three ways of asthma control including SMART, fixed doses with regular
doses and fixed doses with higher doses
3. We will evaluate the efficacy/safety for these not-well controlled patients.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- asthma not well control
Exclusion Criteria:
- COPD
Locations and Contacts
Additional Information
Starting date: March 2009
Last updated: July 23, 2012
|